Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for XOMA Corporation (XOMA : NSDQ)
 
 • Company Description   
XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1? with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California.

Number of Employees: 12

 
 • Price / Volume Information   
Yesterday's Closing Price: $17.21 Daily Weekly Monthly
20 Day Moving Average: 37,748 shares
Shares Outstanding: 11.42 (millions)
Market Capitalization: $196.55 (millions)
Beta: 1.09
52 Week High: $39.02
52 Week Low: $16.96
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -28.91% -22.40%
12 Week -14.51% -7.60%
Year To Date -17.46% -2.23%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2200 POWELL STREET SUITE 310
-
EMERYVILLE,CA 94608
USA
ph: 510-204-7200
fax: 510-649-7571
investorrelations@xoma.com http://www.xoma.com
 
 • General Corporate Information   
Officers
James R. Neal - Chief Executive Officer and Chairman of the Board
Thomas Burns - Senior Vice President; Finance and Chief Financial
W. Denman Van Ness - Director
Joseph M. Limber - Director
Jack L. Wyszomierski - Director

Peer Information
XOMA Corporation (CORR.)
XOMA Corporation (RSPI)
XOMA Corporation (CGXP)
XOMA Corporation (BGEN)
XOMA Corporation (GTBP)
XOMA Corporation (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 98419J206
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 11.42
Most Recent Split Date: 10.00 (0.05:1)
Beta: 1.09
Market Capitalization: $196.55 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.10 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.33 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: 32.47
PEG Ratio: -
Price Ratios
Price/Book: 1.40
Price/Cash Flow: 23.81
Price / Sales: 4.81
EPS Growth
vs. Year Ago Period: 54.29%
vs. Previous Quarter: -119.16%
Sales Growth
vs. Year Ago Period: 728.53%
vs. Previous Quarter: -91.36%
ROE
03/31/22 - 8.77
12/31/21 - 4.93
09/30/21 - 1.39
ROA
03/31/22 - 7.56
12/31/21 - 4.02
09/30/21 - 1.08
Current Ratio
03/31/22 - 11.36
12/31/21 - 7.48
09/30/21 - 11.51
Quick Ratio
03/31/22 - 11.36
12/31/21 - 7.48
09/30/21 - 11.50
Operating Margin
03/31/22 - 27.35
12/31/21 - 14.57
09/30/21 - 4.63
Net Margin
03/31/22 - 27.35
12/31/21 - 14.57
09/30/21 - 4.63
Pre-Tax Margin
03/31/22 - 51.31
12/31/21 - 41.64
09/30/21 - 29.01
Book Value
03/31/22 - 12.27
12/31/21 - 12.54
09/30/21 - 9.86
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©